Transferrins TRIZ Cases

This case shows how n-mer motifs on AAV capsids target TFRC to improve blood-brain barrier crossing and CNS transduction.

Selective ionic elution removes endotoxin from lactoferrin without surfactants, reducing protein loss and production costs.

Linking factor VII to transferrin extends in-vivo half-life and minimizes alloantibody formation without reducing biological activity.

Optimized cation exchange chromatography resolves low yield and difficult purification bottlenecks, achieving over 95% purity.

Coupling a modified transferrin binding domain to DNA polymerase creates recombinant enzymes that resist inhibition by biomacromolecules.

A biopolymer scaffold peptide compound selectively sequesters anti-AChR autoantibodies to treat myasthenia gravis.

Lactoferrin inhibits leukocyte extracellular trap formation to reduce disease severity in ANCA-associated vasculitis without inducing side effects.

Specific protein combinations in cell culture media improve growth rates and viability while reducing stress-related apoptosis during large-scale production.

Cold separation removes fat before expanded bed adsorption purifies lactoferrin, avoiding column clogging and boosting yield.

Engineered IDUA-Fc fusion protein crosses the blood-brain barrier via transferrin receptor binding, treating central nervous system manifestations of MPS I.

Thermotoga neapolitana converts atmospheric carbon dioxide into lactic acid, addressing climate change while generating valuable raw materials.

Fusing anti-inflammatory peptides to a ferritin monomer fragment creates a self-assembling nanocage that targets endothelial cells to reduce sepsis mortality.

Complex coacervation stabilizes lactoferrin within casein structures, preventing denaturation during high-heat sterilization.

Peptide-modified ferritin binds selectively to chromium, molybdenum, or tungsten portions on silicon oxide substrates, overcoming electrostatic limitations.

Peptide-bonding transferrin to G-CSF mutant proteins extends blood stability and simplifies purification compared to chemical PEGylation methods.

A factor VII and transferrin fusion protein formulation uses trehalose to maintain biological activity.

A mutated ferritin protein carries foreign peptides via intracellular delivery.

Sodium chloride and citrate buffers replace harsh alkalis to prevent protein denaturation during expanded bed adsorption.

Removing the fifth helix reduces steric hindrance, allowing large protein fusion without blocking cage formation.

Specific lysine and cysteine mutations in ferritin variants enhance drug encapsulation efficiency while reducing dimer formation and aggregation.

A ferritin protein composition self-assembles into spherical nanoparticles to deliver immune checkpoint inhibitors.

A recombinant promoter drives biosynthesis-supporting polypeptide expression in genetically modified yeast cells.

A method produces low-iron lactoferrin using acid treatment and ultrafiltration to remove iron saturation.

Lactoferrin-derived peptides bind the HA2 fusion peptide, blocking hemagglutination and preventing cell entry across multiple influenza subtypes.

A transferrin receptor ligand covalently links to bactericidal agents to facilitate passage across the blood-brain barrier via receptor-mediated transcytosis.

Co-expressing ferritin heavy and light subunits in microbial hosts to generate heteropolymer molecules with preselected stoichiometric ratios.

A biopolymer scaffold conjugated with peptide n-mers selectively binds and depletes undesirable antibodies from patient circulation.

Peptide-modified ferritin binds selectively to vanadium, niobium, or tantalum portions on silicon oxide substrates.

Engineered polypeptides bind interleukin-1 receptor type-I with high affinity, overcoming poor tissue distribution of large molecule drugs.